In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs. For additional information, please visit https://www.coherus.com.
Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010 and headquartered in Silicon Valley, CA, Coherus is composed of a team of industry veterans with decades of experience in pioneering biologics companies.